TAF9

Transcription initiation factor TFIID subunit 9 · Q16594 · TAF9 on Sugi Atlas →

0 patent compounds predicted against TAF9, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to TAF9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis. PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex nanENROLLING_BY_INVITATION
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Amyotrophic Lateral Sclerosis (ALS) Families Project nanRECRUITING
Immune Interactions in Severe Asthma nanCOMPLETED
Genome-wide Epistasis for Cardiovascular Severity in Marfan Study nanUNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus nanUNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Telomere and Telomerase nanWITHDRAWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia nanCOMPLETED
Family Resilience Initiative Research Program nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TAF9 binder may also engage these)

ProteinNameSimilarity
Q17QQ4 1.000 Q17QQ4 →
Q5BKE0 1.000 Q5BKE0 →
Q8VI33 1.000 Q8VI33 →
Q5R7P7 1.000 Q5R7P7 →
Q62880 1.000 Q62880 →
Q9HBM6 1.000 Q9HBM6 →
Q6NZA9 0.998 Q6NZA9 →
Q91857 0.992 Q91857 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.987 landscape →
P41846 0.986 P41846 →
Q27974 0.986 Q27974 →
P49117 0.985 P49117 →
Q28E45 0.985 Q28E45 →
O75061 0.984 O75061 →
Q8C5L3 0.984 Q8C5L3 →
Q6PIJ4 0.984 Q6PIJ4 →
Q8TC92 0.984 Q8TC92 →
Q32NW2 0.984 Q32NW2 →
P35728 0.984 P35728 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.984 landscape →
Q6PGA0 0.984 Q6PGA0 →
Q6GN21 0.984 Q6GN21 →
P49847 0.984 P49847 →
P97496 0.984 P97496 →
P49848 0.983 P49848 →
Q9VS24 0.983 Q9VS24 →
Q7ZX03 0.983 Q7ZX03 →
SMARCC1 SWI/SNF complex subunit SMARCC1 0.983 landscape →
P81269 0.983 P81269 →
O54772 0.983 O54772 →